NASHVILLE, Tenn., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into an ...
Hosted on MSN
Harrow To Acquire Sedation Solutions Developer Melt Pharmaceuticals – More Details Inside
Harrow (HROW) announced on Friday that it has entered into an agreement to acquire privately held Melt Pharmaceuticals for an undisclosed price. While Harrow is a provider of ophthalmic disease ...
Harrow recently experienced a 24% share price increase over the last quarter, coinciding with its announcement of a $250 million debt financing via senior unsecured notes. This announcement comes at a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback